Immunomodulation With Eltrombopag in ITP

NCT ID: NCT04812483

Last Updated: 2024-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2024-04-11

Brief Summary

The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).

Detailed Description

The randomized open lable study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary ITP. Treatment protocol will be HD-DXM (40 mg PO, day 1-4) with or without eltrombopag (25-50 mg PO, day 5-140) on an outpatient basis. Immunological investigations will be performed before start of treatment and then on week 3, 20 (end of therapy) and 30.

1. Intervention phase:

Medical history and physical examination including assessment of severe bleeding every week until week 4, every second week until week 20. Complete blood count every week until week 10. For the adjustment of the Thrombopoietin receptor agonist (TPO-RA) dose - every second week until week 20. Immunologic panel at the beginning and at week 3 and 20.

2. Follow-up:

Three clinical visits are scheduled in the follow-up including a complete blood count: at week 22, 24 and 30. Immunologic panel will be done at week 30 (end of study).

High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization).

Arm 1: Standard Arm No planed further treatment. = standard therapy. In case of non-response after 2 courses of HD-DXM (week 4): cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2).

In case of relapse: repeat HD-DXM (40 mg day 1-4), up to a maximal of 3 courses. Time between 2 courses should be minimal 14 days. In case of re-relapse after the third course: cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2).

Arm 2: Study Arm Eltrombopag (Revolade®), 50 mg per os, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.

In case of non-response after 4 weeks on eltrombopag: drop out

Conditions

Primary Immune Thrombocytopenia (ITP)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard Arm

HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:

No planed further treatment. = standard therapy (without eltrombopag)

Group Type: OTHER

standard therapy (without eltrombopag): HD-DXM

Intervention Type: DRUG

standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4

Study Arm

HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:

The subjects in the experimental arm will be treated with eltrombopag:

Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows.

Group Type: EXPERIMENTAL

Eltrombopag (Revolade®)

Intervention Type: DRUG

Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.

standard therapy (without eltrombopag): HD-DXM

Intervention Type: DRUG

standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4

Interventions

Eltrombopag (Revolade®)

Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.

Intervention Type: DRUG

standard therapy (without eltrombopag): HD-DXM

standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Informed consent as documented by signature
• Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a risk of platelet count of <30x109/l or risk of severe bleeding
• First-line therapy maximum for 1 week prior to enrolment
• Bleeding severity and quality of life are neither an inclusion nor an exclusion criterion.

Exclusion Criteria

• Patients previously treated for ITP more than 7 days prior to enrolment (e.g. Steroid, intravenous immunoglobulin (IVIG), platelet infusion)
• Patients treated with second-line drugs prior to enrolment
• Life-threatening bleeding (and inability to sign informed consent)
• Secondary ITP
• Positive family history for ITP
• Presence or history of autoimmune disease as judged by the investigator
• Hepatosplenomegaly in the clinical examination
• Relevant hepatic disease as judged by the investigator
• Presence or history of thromboembolic disease
• Patients with splenectomy
• Women who are pregnant or breast feeding
• Intention to become pregnant during the course of the study
• Lack of safe double contraception
• Any vaccination 2 weeks prior start of the study
• Immunsuppressive and antiplatelet drugs
• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, incompetence to judge
• Participation in another study with investigational drug within the 30 days preceding and during the present study
• Enrolment of the investigator, his/her family members, employees and other dependent persons

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stiftung zur Förderung medizinischer und biologischer Forschung

UNKNOWN

Sponsor Role: collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

University of Erlangen-Nürnberg, Department of Biology

UNKNOWN

Sponsor Role: collaborator

University Children's Hospital Basel

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexandra Schifferli, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Children's Hospital Basel, UKBB

Locations

Aarau Cantonal Hospital, Division of Hematology

Aarau, , Switzerland

University Children's Hospital Basel (UKBB)

Basel, , Switzerland

University Hospital Basel, Division of Hematology

Basel, , Switzerland

University Hospital Bern, Division of Hematology

Bern, , Switzerland

Liestal Cantonal Hospital, Division of Hematology

Liestal, , Switzerland

Lucerne Cantonal Hospital, Division of Hematology

Lucerne, , Switzerland

Countries

Switzerland

Other Identifiers

2021-00044; ks19Schifferli

Identifier Type: -

Identifier Source: org_study_id